Target intelligence / Profile preview

Angio-associated migratory cell protein (AAMP)

Target: AAMP
Molecular classification: Immunoglobulin superfamily, WD repeat domain containing (WDR family), Heparin-binding protein, Other (not classified as receptor, enzyme, transporter, etc.)

Overview

Angio-associated migratory cell protein (AAMP) is a conserved, immunoglobulin superfamily protein containing a WD40 domain and a heparin-binding site. It is primarily expressed in the cytosol of vascular endothelial cells and certain cancer cells. Its main biological roles include driving angiogenesis and regulating cell migration—which it does via the RhoA/Rho-kinase signaling pathway. AAMP’s expression and function are relevant in numerous disease processes, especially cancer and cardiovascular disease, where abnormal cell migration and blood vessel formation play critical roles. While AAMP is a promising therapeutic target for diseases involving pathological angiogenesis and cell migration, no approved drugs currently target it directly

Other names: AAMPAngio-associated migratory cell proteinAngio associated migratory cell protein

Mechanism of action

Not established for approved drugs. Mechanistically, targeting AAMP could affect angiogenesis, cell migration, and RhoA pathway modulation

Biological functions

Angiogenesis (formation of new blood vessels)Cell migration (regulation in endothelial and smooth muscle cells, cytotrophoblasts, cancer cells)Endothelial tube formationHeparin-sensitive cell adhesionRhoA/Rho-kinase pathway signaling (involved in cell migration/division)

Disease associations

Cancer (breast, colon, ovarian, cervical, papillary thyroid, pulmonary, glial brain tumors, lymphoma)Cardiovascular disease (atherosclerosis, restenosis)Leukemia (myeloid leukemia: both chronic and acute forms)Gastrointestinal stromal tumor (GIST)Epidermoid carcinomaFamilial Paroxysmal Nonkinesigenic DyskinesiaSpinocerebellar Ataxia 1

Safety considerations

Targeting proteins involved in angiogenesis (like AAMP) could potentially affect vascular health and wound healing (class-wide concern for angiogenesis modulators)No specific safety concerns are documented for targeting AAMP directly, as no clinical drugs exist currently

Interacting drugs

No commonly recognized approved drugs directly targeting AAMP. Some small molecule perturbations that change AAMP expression have been described in high-throughput datasets, but specific drugs are not validated as therapeutic interventions

1 more in the full profile.

Biomarkers

AAMP expression has been correlated with disease status and tissue necrosis in situ in conditions such as GIST, ductal carcinomas, and other malignanciesResearch studies use AAMP expression as a marker of endothelial activation or cancer aggressiveness, but it is not widely established as a clinical biomarker

Beyond the preview

Go deeper on Angio-associated migratory cell protein (AAMP).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Angio-associated migratory cell protein (AAMP).

Explore the full profile